Excerpt about the acquisition of Biohaven taken from Pfizers 10-K for the fiscal year that ended on December 31, 2022.

Acquisition of Biohaven

On October 3, 2022, we acquired Biohaven, the maker of rimegepant, an innovative therapy approved for acute treatment of migraines. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share. On the date of the acquisition we transferred cash of $11,500 million to the shareholders of Biohaven.

This acquisition follows on the November 2021 collaboration agreement in which we acquired 2.6 percent of Biohavens common stock. On October 3, 2022, this 2.6 percent equity interest had a fair (carrying) value of $200 ($150) million.

Per the acquisition agreement, certain former shareholders of Biohaven transferred their shares in exchange for the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant in the U.S. in excess of $5.25 billion. This contingent consideration was determined to have a fair value as of October 3, 2022 of $100 million.

In connection with this business combination, on October 3, 2022, we recorded the following identifiable assets and liabilities:

What effect did the acquisition of biohaven have on Pfizers Equity and Income

(in millions of U.S. dollars)
Trade accounts receivable	398
Inventories	817
Identifiable intangible assets	12,100
Total	13,315
Other current liabilities	477
Long-term debt	1,400
Deferred tax liabilities	566
Total	2,443